https://www.verahealth.ai/ja/news/obstructive-hcm-mavacamten-now-fda-approved-to-improve-symptoms-and-exercise-cap
Obstructive HCM: Mavacamten now FDA-approved to improve symptoms and exercise capacity - Vera...
In a 30-week randomized placebo-controlled trial in NYHA class II–III adults, 37% met the composite clinical response with mavacamten vs 17% with placebo, with...
exercise capacityobstructivehcmmavacamtenfda
https://scholars.duke.edu/publication/1563491
Scholars@Duke publication: Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing...
scholarsdukepublicationeffectsmavacamten